Expertise in
1
conditions

Mireia Margeli

Badalona, CT, ES 
Expertise in
1
conditions
Badalona, CT, ES 

Overview

Mireia Margeli practices practicing medicine in Badalona, Spain.

Ms. Margeli is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, Glycogen Storage Disease Type 6, Triple-Negative Breast Cancer, Mastectomy, and Orchiectomy.

She is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Badalona, CT, Spain
Other Locations
Madrid, MD, Spain
Barcelona, CT, Spain
Girona, CT 17007, Spain
Murcia, MU, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Enrollment Status: Unknown
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: U3 1402
Study Phase: Early Phase 1
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Elacestrant in Preoperative Setting, a Window of Opportunity Study
Elacestrant in Preoperative Setting, a Window of Opportunity Study
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drug: Elacestrant
Study Phase: Early Phase 1
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Neratinib+Endocrine Therapy
Study Phase: Phase 2
Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery
Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

58 Total Publications

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 10, 2026

Frequently Asked Questions about Mireia Margeli

Is Mireia Margeli a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Mireia Margeli is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mireia Margeli participate in research or clinical trials?

Yes. Mireia Margeli has published 58 articles and abstracts on conditions like Breast Cancer. You can view a list of Mireia Margeli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Margeli's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile